

Forum Original Research Communication

Free Fatty Acid Overload Attenuates Ca²⁺ Signaling and NO Production in Endothelial Cells

VICTOR E. ESENABHALU, GABRIELA SCHAEFFER, and WOLFGANG F. GRAIER

ABSTRACT

Hyperlipidemia represents a major risk factor for development of vascular dysfunction and atherosclerosis. Although the unfortunate role of low-density lipoprotein has been clearly demonstrated, the mechanistic pathways through which triglyceride-derived free fatty acids (FFAs) contribute to vascular disorders are not completely understood. Thus, the present study was designed to elucidate the effects of FFAs on cultured endothelial cells. The Ca²⁺ signaling, endothelial nitric oxide synthase (eNOS) activity, and production of superoxide anions ($\cdot\text{O}_2^-$) were monitored in cells treated with bovine serum albumin-conjugated FFA. FFA-loaded cells showed enhanced intracellular Ca²⁺ release in response to ATP, histamine, or the SERCA inhibitor thapsigargin. This effect corresponded to an overall increase in intracellularly stored Ca²⁺. In contrast, autacid-triggered elevation of cytosolic free Ca²⁺ concentration was blunted in FFA-loaded cells due to inhibition of capacitative Ca²⁺ entry. In agreement with the reduced Ca²⁺ signaling, the Ca²⁺-dependent activity of eNOS was reduced under basal conditions and if cells were stimulated with ATP, histamine, or thapsigargin. The attenuated eNOS activity was associated with $\cdot\text{O}_2^-$ release in FFA-loaded cells. These data indicate that FFAs significantly affect endothelial Ca²⁺ signaling, eNOS activity, and $\cdot\text{O}_2^-$ release and, thus, might contribute to vascular dysfunction in atherogenesis. *Antioxid. Redox Signal.* 5, 147–153.

INTRODUCTION

DESPITE THE VARIOUS BIOLOGICAL FUNCTIONS OF FREE FATTY ACIDS (FFAs), disturbances in FFA metabolisms have been implicated in several human vascular diseases. Particularly, the concept that abnormalities in fatty acid metabolism may be the primary metabolic disturbance in non-insulin-dependent diabetes mellitus and obesity has gained momentum over the last decade (5). Vascular disorders, such as atherosclerosis, have been known to account for more premature deaths and long-term disability than any other disorder in industrialized society. The pathologic state of atherosclerosis becomes macroscopically visible in so-called atherosclerotic plaques that represent initially an accumulation of cholesterol on the inside of the arterial wall. To uncover the molecular mechanisms that contribute to early "fatty streak formation,"

macrophage invasion and smooth muscle proliferation, which promote plaque formation, still remain a challenge to vascular science research. Furthermore, whereas the atherosclerotic risk of low-density lipoprotein (3), inflammation (7), or bacterial infection (21) has been clearly demonstrated, the role of FFAs is still under debate. Notably, in a transgenic mouse model with tissue-specific expression of human lipoprotein lipase in the heart and the circulatory system (19), large accumulation of FFAs was associated with severe blood vessel dysfunction (6). In this model, endothelial-dependent relaxation constituted the primary phenomenon, whereas smooth muscle reactivity was only slightly affected. These data are in agreement with the common hypothesis that dysfunction of endothelial cells is involved already in the initial phase of atherogenesis or even represents a primary target of risk factors that are associated with atherosclerosis.

Therefore, a study was designed to assess the effect of FFA overload on autacoid-triggered Ca^{2+} signaling, endothelial nitric oxide synthase (eNOS) activation, and free radical production in the human umbilical vein endothelial cell line EA.hy926.

MATERIALS AND METHODS

Materials

Cell culture chemicals were obtained from Life Technologies (Vienna, Austria). Fetal calf serum (premium quality) and donor horse serum were from PPA Laboratories (Linz, Austria). Petri dishes and cell culture plastic were from Iwaki (Bertoni, Vienna, Austria). Fura-2/AM was purchased from Molecular Probes (Leiden, Netherlands). Buffer salts were from Merck (Vienna, Austria). All other materials were from Sigma (St. Louis, MO, U.S.A.).

Cell culture

The human umbilical vein endothelial cell line EA.hy926 was a kind gift from Dr. Cora-Jean S. Edgell (Pathology Division, University of North Carolina, Chapel Hill, NC, U.S.A.). Endothelial cells of passages higher than 43 were used. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum and 1% HAT (5 mM hypoxanthine, 20 μM aminopterin, and 0.8 mM thymidine).

Preparation of sodium oleate-albumin complex solution (SOACS)

In an attempt to produce a high FFA loading in cells, endothelial cells (EA.hy926) were preincubated in SOACS. This solution is prepared by modification of the method of Van Harken *et al.* (31). Oleic acid (22.5 mg) was transferred to a 20-ml beaker containing 0.5 ml of ethanol, and 25 μl of 5 M NaOH was added followed by thorough mixing. The ethanol was removed by evaporation under nitrogen, and 2.5 ml of 150 mM NaCl solution was added. The clear solution was heated for 3–5 min at 60°C. While the fatty acid solution was still warm, 3.1 ml of ice-cold 24% (wt/vol) bovine albumin in 150 mM NaCl was added rapidly and stirred for 10 min. The final volume was adjusted to 6.25 ml with 24% (wt/vol) bovine albumin in 150 mM NaCl, and the SOACS was kept frozen at -20°C until use. The 24% (wt/vol) bovine albumin solution was prepared by adding 3 g of bovine serum albumin (Sigma Chemicals, Vienna, Austria) to 8.8 ml of 150 mM NaCl. The albumin was added in six aliquots (0.5 g per aliquot) over a 5-h period while the mixture was being stirred at room temperature. The solution was adjusted to a final pH of 7.4 with 5 M NaOH, and final volume was adjusted to 12.5 ml with 150 mM NaCl. To perform a concentration-response correlation analysis, SOACS was diluted with equally concentrated bovine serum solution. The solution was kept at -20°C until use. In general, cells were preincubated with SOACS for 4 h in culture medium. Control cells were treated with the bovine serum albumin at the same concentration (*i.e.*, 2.4%).

Ca^{2+} measurement

Intracellular Ca^{2+} concentration was determined using Ca^{2+} -dye fluorescence techniques for fura-2 as previously described (13). Cultured cells were harvested by 3 min of trypsin, centrifuged, resuspended in DMEM containing 2 μM fura-2/AM, and kept at room temperature. After 45 min at room temperature, cells were centrifuged and the DMEM changed and allowed another 10 min at room temperature. One milliliter of the cell suspension was transferred into a test tube, centrifuged, and resuspended in 2 ml of HEPES-buffered solution containing the following (in mM): 2.5 CaCl_2 , 145 NaCl, 5 KCl, 1 MgCl_2 , 10 HEPES acid, 10^{-5} EGTA (pH adjusted to 7.4). Intracellular Ca^{2+} was monitored in suspended cells in a thermostatically controlled fluorescence spectrometer (Hitachi F-2000). Changes in Ca^{2+} concentration were monitored by measuring the ratio of fluorescence at 340 and 380 nm excitation (F_{340}/F_{380}) and 510 nm emission. For calculation of the nanomolar free Ca^{2+} concentration from the ratio (F_{340}/F_{380}) units obtained, an *in situ* calibration curve was used as previously described (9).

Measurement of eNOS activity

Activity of eNOS (in the FFA and control groups) was determined by measuring the conversion of L-[^3H]arginine to L-[^3H]citrulline, similar to the procedure described previously (15, 23). Endothelial cells of the two groups were cultured in six-well plastic dishes. At confluence, cultured medium was removed, and cells were washed twice with phosphate buffer solution containing the following (in mM): 137 NaCl, 2.7 KCl, 8 Na_2HPO_4 , 1.5 KH_2PO_4 (pH adjusted to 7.4). The experiment was commenced by the addition of 900 μl of HEPES buffer plus 2.5 mM Ca^{2+} , containing 2×10^6 d.p.m. L-[^3H]arginine and 100 μl of either buffer (*i.e.*, control) or agonists, histamine (10 μM final), thapsigargin (1 μM final), and ATP (10 μM). In parallel series, experiments were repeated in the presence of 300 μM L- N^G -nitro-arginine and performed for each condition. After a 15-min incubation period, buffer was discarded, cells were washed three times with chilled Ca^{2+} -free HEPES buffer, and lysed with 1 ml of 0.01 M HCl. After 1 h at 4°C , the total incorporated radioactivity was measured in a 100- μl aliquot. The remaining 0.9 ml of HCl was buffered with 100 μl of 200 mM sodium acetate buffer (pH 13.0) containing 10 mM L-citrulline. The amino acids L-[^3H]arginine and L-[^3H]citrulline were separated using column chromatography as described recently (15, 23). Activity of eNOS was calculated by the L- N^G -nitro-arginine-sensitive percentage of the conversion of L-[^3H]arginine to L-[^3H]citrulline.

Superoxide anion ($\cdot\text{O}_2^-$) measurements

As described previously (8), confluent EA.hy926 cells preincubated with 150 μl of SOACS and control cells were used in these experiments. Cells were harvested with trypsin (2 min), centrifuged, and resuspended in 990 μl of phosphate buffer solution and 10 μl of ferricytochrome C solution (1 mM). After the respective incubation time, cells were centrifuged and the supernatant was transferred into a cuvette for measurements. Immediately after the cells were mixed with the ferricytochrome C solution, a first reading was taken fol-

lowed by an incubation period of 1 h. Thereafter, superoxide dismutase (SOD; 500 U/ml) was added, and an intimate reading following by an incubation time of 15 min prior to the last readings was performed. The $\cdot\text{O}_2^-$ release from the FFA-loaded endothelial cells was monitored in the spectrophotometer at 550 nm emission. Differences in extinction in the absence and presence of SOD [$E_{\text{O}_2^-} = E_{-\text{SOD}} - 4 \times (E_{+\text{SOD}})$] represent $\cdot\text{O}_2^-$ -related reduction of ferricytochrome C and can be calculated using the molar extinction coefficient of the reduced form of ferricytochrome C ($\epsilon = 21.000$) (29).

Statistics

Data are expressed as means \pm SE. Statistical analysis was performed using paired samples *t* test with Bonferroni correction for multiple comparisons. Data are considered significant if $p < 0.05$.

RESULTS

In control cells, addition of $1 \mu\text{M}$ histamine evoked a fast and transient Ca^{2+} elevation followed by a long-lasting and stable plateau phase (Fig. 1A). In contrast, in SOACS-treated




FIG. 1. Effect of SOACS treatment on endothelial Ca^{2+} signaling in response to histamine. Cultured endothelial cells were treated for 4 h in culture medium containing 2.4% bovine serum albumin without and with oleic acid (360 $\mu\text{g}/\text{ml}$ oleic acid; FFA). Final oleic acid concentration was 360 $\mu\text{g}/\text{ml}$. (A) Original tracing of the Ca^{2+} signaling initiated by $1 \mu\text{M}$ histamine in Ca^{2+} -containing solution in control (thin line, μ ; $n = 8$) and SOACS (thick line, λ ; $n = 8$) treated cells. (B) Intracellular Ca^{2+} release in response to $1 \mu\text{M}$ histamine in control ($n = 18$) and FFA-loaded cells ($n = 16$). (C) Histamine-induced Ca^{2+} entry visualized by addition of 2.5 mM extracellular Ca^{2+} to prestimulated cells (control, $n = 18$; FFA, $n = 16$). * $p < 0.05$ vs. control.

cells, the initial transient Ca^{2+} elevation in response to $1 \mu\text{M}$ histamine was reduced by $\sim 25\%$ and no plateau phase occurred (Fig. 1A). In order to differentiate between intracellular Ca^{2+} release and Ca^{2+} influx, endothelial cells were stimulated in the nominal absence of extracellular Ca^{2+} with $1 \mu\text{M}$ histamine (*i.e.*, intracellular Ca^{2+} release), followed by a readition of 2.5 mM extracellular Ca^{2+} (*i.e.*, Ca^{2+} entry). Notably, histamine-induced intracellular Ca^{2+} release was slightly increased in SOACS-treated cells (Fig. 1B), whereas Ca^{2+} entry was prevented in FFA-loaded cells (Fig. 1C). Furthermore, a concentration-response curve for histamine was conducted in control cells and in SOACS-treated cells (Fig. 2A). In general, FFA loading reduced the maximal effect by $\sim 25\%$, whereas the EC_{50} remained unchanged [control: 0.42 (0.11 – 1.57) μM , $n = 12$; SOACS-treated: 0.70 (0.23 – 2.11) μM , $n = 11$].

In agreement with our data obtained with histamine, treatment of endothelial cells with SOACS reduced ATP-evoked Ca^{2+} signaling by $\sim 20\%$, whereas the EC_{50} for ATP was unaffected by the FFA-loading procedure [control: 2.22 (1.62 – 3.04) μM , $n = 17$ – 22 ; SOACS-treated: 2.41 (1.73 – 3.35) μM , $n = 17$ – 21]. Furthermore a concentration-effect correlation for SOACS on endothelial Ca^{2+} signaling evoked by $1 \mu\text{M}$ histamine was performed (Fig. 3).




FIG. 2. Effect of FFA loading on sensitivity to histamine and ATP to evoke Ca^{2+} signaling. Endothelial cells were incubated for 4 h with bovine serum albumin (control, μ) or SOACS (360 $\mu\text{g}/\text{ml}$ oleic acid; FFA, λ). Concentration-response curves to histamine (A; control, $n = 12$; FFA, $n = 11$) and ATP (B; control, $n = 17$ – 22 ; FFA, $n = 17$ – 21) were performed in 2.5 mM Ca^{2+} containing buffer. * $p < 0.05$ vs. control.




FIG. 3. Concentration-response correlation for SOACS on histamine-induced signaling. Cultured endothelial cells were preincubated for 4 h with SOACS containing the final oleic acid concentrations indicated. Intracellular Ca²⁺ signaling in response to 1 μM histamine was monitored and expressed as % of that measured in cells treated with bovine serum albumin alone ($n = 17-20$). * $p < 0.05$ vs. control.

In order to investigate whether the inhibitory effect of the SOACS treatment on endothelial Ca²⁺ signaling was due to an inhibitory effect on receptor-effector coupling, the effect of the smooth endoplasmic reticulum Ca²⁺ antiporter (SERCA) inhibitor thapsigargin was tested. As shown in Fig. 4A, the ef-




FIG. 4. Effect of SOACS treatment on endothelial Ca²⁺ signaling in response to thapsigargin. After a 4-h incubation with or without SOAC (360 μg/ml oleic acid), cells were loaded with fura-2/AM and changes in intracellular free Ca²⁺ concentration due to 1 μM thapsigargin in Ca²⁺-containing buffer (A; control, $n = 13$; FFA, $n = 14$) and in Ca²⁺-free solution (B; control, $n = 15$; FFA, $n = 12$) were monitored. (C) Thapsigargin-induced Ca²⁺ entry visualized by addition of 2.5 mM extracellular Ca²⁺ to prestimulated cells (control, $n = 18$; FFA, $n = 16$). * $p < 0.05$ vs. control.

fect of 1 μM thapsigargin to elevate cytosolic free Ca²⁺ concentration in the presence of extracellular Ca²⁺ was strongly reduced in SOACS-treated cells. A further evaluation in a Ca²⁺-free environment revealed an increased intracellular Ca²⁺ release from thapsigargin-sensitive Ca²⁺ stores in FFA-loaded cells (Fig. 4B), whereas thapsigargin-initiated capacitative Ca²⁺ entry (CCE) was reduced by ~73% (Fig. 4C).

Thus, these data with thapsigargin supported our findings that SOACS loading results in an overall increase in releasable Ca²⁺ in intracellular Ca²⁺ pools (presumably the endoplasmic reticulum), whereas CCE is strongly inhibited. To evaluate the amount of overall releasable Ca²⁺ stored in intracellular Ca²⁺ pools, endothelial cells were challenged by the Ca²⁺ ionophore ionomycin. In control cells, 100 nM ionomycin increased [Ca²⁺]_i in the nominal absence of extracellular Ca²⁺ up to 571 ± 11 nM ($n = 12$). In SOACS-treated cells, the effect of 100 nM ionomycin to elevate [Ca²⁺]_i in nominal Ca²⁺-free solution was enhanced (643 ± 7 nM, $n = 14$; $p < 0.05$ versus control cells). Remarkably, CCE visualized by the addition of extracellular Ca²⁺ to ionomycin-treated cells (100 nM) did not differ within the control and SOACS-treated cells (data not shown).

To evaluate further the effect of SOACS loading on endothelial vascular function, eNOS activity measurements were performed. Basal eNOS activity was reduced by 70% in FFA-loaded cells (Fig. 5A). Hence, the stimulatory effects of




FIG. 5. Alterations of eNOS activity and ·O₂⁻ release in endothelial cells due to SOACS treatment. Activity of eNOS (A; control, $n = 4$; FFA, $n = 4$) and the release of ·O₂⁻ (B; control, $n = 6$; FFA, $n = 6$) were measured in cultured endothelial cells pretreated for 4 h with 2.4% bovine serum albumin or SOACS (360 μg/ml oleic acid). * $p < 0.05$ vs. control.

histamine (10 μM), ATP (100 μM), and thapsigargin (1 μM) were diminished in SOACS-treated cells and did not exceed basal eNOS activity in the control cells (Fig. 5A). The reduced eNOS activity in SOACS-loaded endothelial cells was further associated with an increased release of $\cdot\text{O}_2^-$ by $\sim 102\%$ (Fig. 5B).

DISCUSSION

Hyperlipidemia as a risk factor for vascular dysfunction has been widely reported. A pathologic state characterized by accumulation of fatty materials on the inside of the arterial wall to form plaque is evident in atherosclerosis (33). In addition, the concept that abnormalities in fatty acid metabolism may be the primary metabolic disturbance in non-insulin-dependent diabetes and obesity has gained momentum over the last decade (5). Although several literature reports have implicated FFA overload in many human vascular diseases, the mechanistic pathways involved in the development of vascular dysfunction have remained unresolved. Based on our previous report that revealed vascular dysfunction in an animal model overexpressing human lipoprotein lipase in the mouse vascular bed, which was accompanied by increased FFA content in the vasculature (6), in the present study we have tested the impact of FFA loading on various cell functions of cultured endothelial cells. We have elucidated the effects of FFA overload of the endothelial cells on autacoid-evoked Ca^{2+} signaling and eNOS activity and assessed the release of $\cdot\text{O}_2^-$ in response to FFA overload.

Autacoid-induced Ca^{2+} signaling in endothelial cells was significantly reduced in FFA-loaded cells. Interestingly, the reduction was not due to a receptor-desensitizing phenomenon as the EC_{50} for either histamine or ATP did not differ between control and FFA-loaded cells. On the other side, the reduction of Ca^{2+} increases evoked by one given agonist concentration was attenuated in the FFA-loaded cells over the whole concentration range tested. Despite this clear reduction in Ca^{2+} elevation upon autacoids in the presence of extracellular Ca^{2+} , a more detailed analysis of the correlation of FFA loading and endothelial Ca^{2+} signaling revealed an increased intracellular Ca^{2+} release upon stimulation with histamine, whereas CCE, which was visualized by the addition of extracellular Ca^{2+} to cells that were prestimulated in Ca^{2+} -free buffer, was strongly reduced. We have previously shown that pretreatment of endothelial cells with elevated D-glucose resulted in elevated inositol 1,4,5-trisphosphate formation, which, in turn, resulted in an enhanced intracellular Ca^{2+} release in response to agonists (32). However, intracellular Ca^{2+} release induced by thapsigargin, which depletes endoplasmic reticulum independently of inositol 1,4,5-trisphosphate by inhibition of SERCA, was elevated in FFA-loaded cells. Furthermore, ionomycin-triggered intracellular Ca^{2+} release was also found to be enhanced in SOACS-treated cells. These data point to an increased Ca^{2+} content of the endoplasmic reticulum and/or increased endoplasmic reticulum lumen in cells loaded with FFA.

Despite the increase in intracellular stored Ca^{2+} in FFA-loaded cells, histamine-activated CCE, which was visualized

by the addition of extracellular Ca^{2+} to prestimulated cells, was reduced by FFA loading. In agreement with these results, the receptor-independent CCE evoked by thapsigargin was strongly diminished in SOACS-treated endothelial cells. These data demonstrate that an overload of endothelial cells results in reduction of CCE activity independently of intracellular Ca^{2+} release processes. The mechanisms of CCE activation in endothelial cells remain a mystery, although various hypotheses have been suggested (2). Among them, protein-protein coupling between the putative Ca^{2+} channels (35) and the inositol 1,4,5-trisphosphate receptor (2), channel trafficking (28), and several diffusible factors have been proposed to be responsible for transmitting a signal for channel activation if the endoplasmic reticulum becomes depleted (24, 25). As diffusible factors that were proposed to activate CCE, a small nonprotein factor processing a phosphate group (26) that is degraded by Ca^{2+} and phosphatases (27) and arachidonic acid derivatives from the epoxygenase (1, 14, 16) or lipoxygenase (12) pathway have been suggested. Common to all proposed diffusible factors is that their release/production/activation occurs upon depletion of the endoplasmic reticulum. As it became obvious that FFA-loading did not affect intracellular Ca^{2+} release and depletion of the endoplasmic reticulum by the inositol 1,4,5-trisphosphate-activating autacoids histamine and ATP, as well as the SERCA inhibitor thapsigargin (30), it seems unlikely that the reduced CCE in SOACS-loaded cells is due to alterations in Ca^{2+} release processes. Thus, the reduced Ca^{2+} entry might be due to an alteration in CCE activation or in the activity of the channels that are responsible for the CCE. Although the latter seems reasonable as changes in FFA composition of the membrane due to SOACS treatment might affect channel function, our findings that CCE in response to 100 nM ionomycin did not differ between the control and the SOACS-treated cells suggest that mechanisms of CCE activation and the channel activity remained unchanged in FFA-loaded cells. If neither the activation mechanisms nor the activity of CCE is altered, how does SOACS treatment affect endothelial CCE? Recently, mitochondrial Ca^{2+} signaling got attention for CCE activation as it became obvious that mitochondrial Ca^{2+} sequestration crucially facilitates CCE by buffering subplasmalemmal Ca^{2+} concentration to avoid Ca^{2+} -mediated inactivation of the CCE channels (10, 11, 17, 18). Notably, as a consequence of its property to act as a Ca^{2+} ionophore, ionomycin-induced CCE was found to be independent of this mitochondrial Ca^{2+} buffering function. As mitochondrial respiratory functions and proliferation are controlled by FFAs (34), it is tempting to speculate that SOACS loading affects mitochondrial Ca^{2+} buffering function and, thus, prevents CCE. Furthermore, saturated but not unsaturated FFAs have been described to contribute to a Ca^{2+} -activated ion pore in the mitochondria that might be responsible for the rapid Ca^{2+} sequestration of the mitochondria (22). An overload with oleic acid by SOACS treatments might affect mitochondrial FFA content and, thus, the formation of Ca^{2+} -activated ion pores in the mitochondrial membrane, thus preventing mitochondrial Ca^{2+} buffering and, in turn, CCE activity. Further studies are necessary to prove the impact of FFA overload on mitochondrial Ca^{2+} function.

The stimulation of eNOS activation has been found to be essential due to an activation of Ca^{2+} influx (20). In line with these reports, SOACS treatment that blunted CCE further di-

minished eNOS activation in response to histamine, ATP, and thapsigargin. Interestingly, basal eNOS activity was found to be reduced in SOACS-treated cells also. Whether this effect is due to the attenuation of basal Ca^{2+} influx in FFA-loaded cells, the lack of supplementary cofactors, or alterations in eNOS distribution is unclear and the subject of further studies. Nevertheless, these findings are in agreement with our recent report that increased FFA content of blood vessels reduce nitric oxide production (6). In line with this previous work, we also have found an increased release of $\cdot\text{O}_2^-$. An increased $\cdot\text{O}_2^-$ release in the vasculature has been proven to scavenge nitric oxide to be active in the smooth muscle cells (4), thus promoting vascular dysfunction and atherogenesis.

The reported alterations of endothelial function by FFA overload further indicate that FFA contribute to vascular complications. Although the molecular mechanisms of action need further investigation, the consequences on vessel reactivity clearly point to a reduction of the biosynthesis and the bioactivity of nitric oxide.

ABBREVIATIONS

CCE, capacitative Ca^{2+} entry; DMEM, Dulbecco's modified Eagle's medium; eNOS, endothelial nitric oxide synthase; FFA, free fatty acid; $\cdot\text{O}_2^-$, superoxide anion; SERCA, smooth endoplasmic reticulum Ca^{2+} antiporter; SOACS, sodium oleate-albumin complex solution; SOD, superoxide dismutase.

ACKNOWLEDGMENTS

The authors wish to thank Mrs. Beatrix Petschar and Mrs. Anna Schreilechner for their excellent technical assistance and Dr. C.J.S. Edgell for the EA.hy926 cells. V.E.E. was supported by the Austrian Academic Exchange Service. This work was supported by the Austrian Funds (P-14586-PHA and SFB 714) and the Austrian Nationalbank (P7542). The Department of Medical Biochemistry and Medical Molecular Biology is a member of the Institutes of Basic Medical Sciences at the University of Graz and was supported by the infrastructure program (UGP4) of the Austrian Ministry of Education, Science and Culture.

REFERENCES

- Alvarez J, Montero M, and Garcia-Sancho J. Cytochrome P450 may regulate plasma membrane Ca^{2+} permeability according to the filling state of the intracellular Ca^{2+} stores. *FASEB J* 6: 786–792, 1992.
- Berridge MJ. Capacitative calcium entry. *Biochem J* 312: 1–11, 1995.
- Bucala R. Lipid and lipoprotein modification by advanced glycosylation end-products: role in atherosclerosis. *Exp Physiol* 82: 327–337, 1997.
- Cohen R. Dysfunction of vascular endothelium in diabetes mellitus. *Circulation* 87 (Suppl V): V67–V76, 1993.
- Dixon JL. Bimonthly update: lipidology. Lipid metabolism. *Curr Opin Lipidol* 8: U81–U83, 1997.
- Esenabhalu VE, Cerimagic M, Malli R, Osibow K, Levak-Frank S, Frieden M, Sattler W, Kostner GM, Zechner R, and Graier WF. Tissue-specific expression of human lipoprotein lipase in the vascular system affects vascular reactivity in transgenic mice. *Br J Pharmacol* 135: 143–154, 2002.
- Farmer JA and Torre-Amione G. Atherosclerosis and inflammation. *Curr Atheroscler Rep* 4: 92–98, 2002.
- Fleischhacker E, Esenabhalu VE, Spitaler M, Holzmann S, Skrabal F, Koidl B, Kostner GM, and Graier WF. Human diabetes is associated with hyperreactivity of vascular smooth muscle cells due to altered subcellular Ca^{2+} distribution. *Diabetes* 48: 1323–1330, 1999.
- Frieden M, Malli R, Samardzija M, Demaurex N, and Graier WF. Subplasmalemmal endoplasmic reticulum controls K_{Ca} channel activity upon stimulation with moderate histamine concentration in a human umbilical vein endothelial cell line. *J Physiol* 540: 73–84, 2002.
- Gilbert JA and Parekh AB. Respiring mitochondria determine the pattern of activation and inactivation of the store-operated Ca^{2+} current I_{CRAC} . *EMBO J* 19: 6401–6407, 2000.
- Gilbert JA, Bakowski D, and Parekh AB. Energized mitochondria increase the dynamic range over which inositol 1,4,5-trisphosphate activates store-operated calcium influx. *EMBO J* 20: 2672–2679, 2001.
- Glitsch MD, Bakowski D, and Parekh AB. Effects of inhibitors of the lipo-oxygenase family of enzymes on the store-operated calcium current I_{CRAC} in rat basophilic leukaemia cells. *J Physiol* 539: 93–106, 2002.
- Graier WF, Wascher TC, Lackner L, Toplak H, Krejs GJ, and Kukovetz WR. Exposure to elevated D-glucose concentrations modulates vascular endothelial cell vasodilatory response. *Diabetes* 42: 1497–1505, 1993.
- Graier WF, Simecek S, and Sturek M. Cytochrome P450 mono-oxygenase-regulated signalling of Ca^{2+} entry in human and bovine endothelial cells. *J Physiol* 482: 259–274, 1995.
- Graier WF, Simecek S, Kukovetz WR, and Kostner GM. High D-glucose-induced changes in endothelial Ca^{2+} /EDRF signaling are due to generation of superoxide anions. *Diabetes* 45: 1386–1395, 1996.
- Hoebel BG, Kostner GM, and Graier WF. Activation of microsomal cytochrome P450 mono-oxygenase by Ca^{2+} store depletion and its contribution to Ca^{2+} entry in porcine aortic endothelial cells. *Br J Pharmacol* 121: 1579–1588, 1997.
- Hoth M, Fanger CM, and Lewis RS. Mitochondrial regulation of store-operated calcium signaling in T lymphocytes. *J Cell Biol* 137: 633–648, 1997.
- Hoth M, Button DC, and Lewis RS. Mitochondrial control of calcium-channel gating: a mechanism for sustained signaling and transcriptional activation in T lymphocytes. *Proc Natl Acad Sci SA* 97: 10607–10612, 2000.
- Levak-Frank S, Hofmann W, Weinstock PH, Radner H, Sattler W, Breslow JL, and Zechner R. Induced mutant mouse lines that express lipoprotein lipase in cardiac muscle, but not in skeletal muscle and adipose tissue, have normal

- plasma triglyceride and high-density lipoprotein-cholesterol levels. *Proc Natl Acad Sci U S A* 96: 3165–3170, 1999.
20. Lückhoff A, Pohl U, Mülsch A, and Busse R. Differential role of extra- and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells. *Br J Pharmacol* 95: 189–186, 1988.
 21. Mahony JB and Coombes BK. Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role? *FEMS Microbiol Lett* 197: 1–9, 2001.
 22. Mironova GD, Gateau-Roesch O, Levrat C, Gritsenko E, Pavlov E, Lazareva AV, Limarenko E, Rey C, Louisot P, and Saris NE. Palmitic and stearic acids bind Ca^{2+} with high affinity and form nonspecific channels in black-lipid membranes. Possible relation to Ca^{2+} -activated mitochondrial pores. *J Bioenerg Biomembr* 33: 319–331, 2001.
 23. Paltauf-Doburzynska J, Posch K, Paltauf G, and Graier WF. Stealth ryanodine-sensitive Ca^{2+} release contributes to activity of capacitative Ca^{2+} entry and nitric oxide synthase in bovine endothelial cells. *J Physiol* 513: 369–379, 1998.
 24. Putney JW. The capacitative model for receptor-activated calcium entry. *Adv Pharmacol* 22: 251–269, 1991.
 25. Putney JW, Broad LM, Braun FJ, Lievreumont JP, and Bird GSJ. Mechanisms of capacitative calcium entry. *J Cell Sci* 114: 2223–2229, 2001.
 26. Randriamampita C and Tsien RY. Emptying of intracellular Ca^{2+} stores releases a novel small messenger that stimulates Ca^{2+} influx. *Nature* 364: 809–814, 1993.
 27. Randriamampita C and Tsien RY. Degradation of a calcium influx factor (CIF) can be blocked by phosphatase inhibitors or chelation of Ca^{2+} . *J Biol Chem* 270: 29–32, 1995.
 28. Somasundaram B, Norman JC, and Mahaut-Smith MP. Primaquine, an inhibitor of vesicular transport, blocks the calcium-release-activated current in rat megakaryocytes. *Biochem J* 309: 725–729, 1995.
 29. Steinbrecher UP. Role of superoxide in endothelial-cell modification of low-density lipoproteins. *Biochim Biophys Acta* 959: 20–30, 1988.
 30. Thastrup O, Dawson AP, Scharff O, Foder B, Cullen PJ, Droback BK, Bjerrum P, Christensen SB, and Hanley MR. Thapsigargin, a novel molecular probe for studying intracellular calcium release and storage. *Agents Actions* 27: 17–23, 1989.
 31. Van Harken DR, Dixon CW, and Heimberg M. Hepatic lipid metabolism in experimental diabetes. V. The effect of concentration of oleate on metabolism of triglycerides and on ketogenesis. *J Biol Chem* 244: 2278–2285, 1969.
 32. Wascher TC, Toplak H, Krejs GJ, Simecek S, Kukovetz WR, and Graier WF. Intracellular mechanisms involved in D-glucose-mediated amplification of agonist-induced Ca^{2+} response and EDRF formation in vascular endothelial cells. *Diabetes* 43: 984–991, 1994.
 33. Wissler RW. Update on the pathogenesis of atherosclerosis. *Am J Med* 91: 3–9, 1991.
 34. Zechner R. The tissue-specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism. *Curr Opin Lipidol* 8: 77–88, 1997.
 35. Zhu X, Jiang M, Peyton MJ, Boulay G, Hurst R, Stefani E, and Birnbaumer L. *trp*, a novel mammalian gene family essential for agonist-activated capacitative Ca^{2+} influx. *Cell* 85: 661–671, 1996.

Address reprint requests to:

Dr. Wolfgang F. Graier

Department of Medical Biochemistry and Medical Molecular

Biology

Karl-Franzens University of Graz

Harrachgasse 21/111

A-8010 Graz

Austria

E-mail: wolfgang.graier@uni-graz.at

Received for publication October 4, 2002; accepted November 27, 2002.

This article has been cited by:

1. A. Gordon Smith. 2012. Impaired glucose tolerance and metabolic syndrome in idiopathic neuropathy. *Journal of the Peripheral Nervous System* **17**, 15-21. [[CrossRef](#)]
2. Y. Tang, G. Li. 2011. Chronic exposure to high fatty acids impedes receptor agonist-induced nitric oxide production and increments of cytosolic Ca²⁺ levels in endothelial cells. *Journal of Molecular Endocrinology* . [[CrossRef](#)]
3. Yu Wang. 2011. Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2. *British Journal of Pharmacology* no-no. [[CrossRef](#)]
4. Joern R. Steinert , Amanda W. Wyatt , Ron Jacob , Giovanni E. Mann . 2009. Redox Modulation of Ca²⁺ Signaling in Human Endothelial and Smooth Muscle Cells in Pre-Eclampsia. *Antioxidants & Redox Signaling* **11**:5, 1149-1163. [[Abstract](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
5. A. Gordon Smith, Kristi Rose, J. Robinson Singleton. 2008. Idiopathic neuropathy patients are at high risk for metabolic syndrome#. *Journal of the Neurological Sciences* **273**:1-2, 25-28. [[CrossRef](#)]
6. A Gordon Smith, J Robinson Singleton. 2008. Impaired Glucose Tolerance and Neuropathy. *The Neurologist* **14**:1, 23-29. [[CrossRef](#)]
7. Yuahn-Sieh Huang, Seu-Mei Wang, Kwan-Lih Hsu, Yung-Zu Tseng, Jiahn-Chun Wu. 2007. Mechanism of oleic acid-induced myofibril disassembly in rat cardiomyocytes. *Journal of Cellular Biochemistry* **102**:3, 638-649. [[CrossRef](#)]
8. D A Ishola, J A Post, M M van Timmeren, S J L Bakker, R Goldschmeding, H A Koomans, B Braam, J A Joles. 2006. Albumin-bound fatty acids induce mitochondrial oxidant stress and impair antioxidant responses in proximal tubular cells. *Kidney International* **70**:4, 724-731. [[CrossRef](#)]
9. Alexandra Kadl , Norbert Leitinger . 2005. The Role of Endothelial Cells in the Resolution of Acute Inflammation. *Antioxidants & Redox Signaling* **7**:11-12, 1744-1754. [[Abstract](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
10. A. N. Faria, F. F. Ribeiro Filho, N. E. Kohlmann, S. R. Gouvea Ferreira, M. T. Zanella. 2005. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. *Diabetes, Obesity and Metabolism* **7**:3, 246-253. [[CrossRef](#)]
11. M. Halle, P. Eriksson, P. Tornvall. 2005. Effects of free fatty acids and a triglyceride-rich fat emulsion on endothelial nitric oxide synthase. *European Journal of Clinical Investigation* **35**:2, 154-155. [[CrossRef](#)]
12. SUDHA S. SHANKAR, BAHRAM MIRZAMOHAMMADI, JAMES P. WALSH, HELMUT O. STEINBERG. 2004. l-Carnitine May Attenuate Free Fatty Acid-Induced Endothelial Dysfunction. *Annals of the New York Academy of Sciences* **1033**:1, 189-197. [[CrossRef](#)]
13. M. Bayerle-Eder, E. Polska, A. Kopf, M. Roden, W. Waldhausl, H. Pleiner, B. Wipler, M. Wolzt, L. Schmetterer. 2004. Free fatty acids exert a greater effect on ocular and skin blood flow than triglycerides in healthy subjects. *European Journal of Clinical Investigation* **34**:8, 519-526. [[CrossRef](#)]
14. Paolo M. Suter. 2004. Alcohol, nutrition and health maintenance: selected aspects. *Proceedings of the Nutrition Society* **63**:01, 81-88. [[CrossRef](#)]
15. Valery N. Bochkov , Norbert Leitinger . 2003. Redox Regulation of Endothelial Function. *Antioxidants & Redox Signaling* **5**:2, 145-146. [[Citation](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]